Cytek Biosciences, Inc.
HealthcareNASDAQ:CTKB · NASDAQ Global Select
-$0.06 today
Vol 1.82M · Avg 0.84M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-19.5%
avg -14.8%
ROIC
-10.3%
avg -6.7%
ROA
-14.4%
avg -4.6%
Analysis
ROIC is currently the strongest return metric at -10.3% versus its period average of -6.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Wenbin Jiang | President, Chief Executive Officer & Chairman of the Board | $1.12M | — | 62 | $5.49M | 4.25% |
Valerie T. Barnett | Chief Legal Officer & Corporate Secretary | $674,943.00 | — | 51 | $217,018.00 | 0.17% |
William D. McCombe | Chief Financial Officer | $660,979.00 | — | 68 | $246,091.00 | 0.19% |
Ming Yan | Chief Technology Officer & Director | $607,420.00 | — | 63 | $4.93M | 3.82% |
Philippe Busque | Senior Vice President of Global Sales & Services | $521,730.00 | — | 55 | $127,675.00 | 0.10% |
Patrik Sebastian Jeanmonod | Head of Corporate Development Analytics | $358,181.00 | — | 60 | $99,377.00 | 0.08% |
Paul D. Goodson | Head of Investor Relations | — | — | — | $246,091.00 | 0.19% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +27.6% | +5.0% (6yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +27.6% over three years. Forward estimates point to Revenue at +5.0% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
CeriBell, Inc.
NASDAQ:CBLL
$700.80M
Surmodics, Inc.
SRDX
$614.51M
AngioDynamics, Inc.
NASDAQ:ANGO
$499.96M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
OrthoPediatrics Corp.
NASDAQ:KIDS
$457.71M
ClearPoint Neuro, Inc.
NASDAQ:CLPT
$403.06M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Organogenesis Holdings Inc.
NASDAQ:ORGO
$301.10M
Treace Medical Concepts, Inc.
NASDAQ:TMCI
$263.38M
Who manages CTKB?
Cytek Biosciences, Inc. (CTKB) lists 7 active executives. The top listed executive is Ming Yan, Chief Technology Officer & Director.
Are CTKB insiders buying or selling?
Recent insider activity shows net buying of $3.23M.
Explore More
Continue the stock analysis
Jump to another research area for this company.